Related references
Note: Only part of the references are listed.L-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
Jennifer N. Leibovitch et al.
BLOOD REVIEWS (2022)
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline
Amrana Qureshi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Inflammation in sickle cell disease
Nicola Conran et al.
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION (2018)
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
K. I. Ataga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sickle Cell Disease
Frederic B. Piel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea
Camila Bononi Almeida et al.
BLOOD (2015)
Hydroxyurea therapy for sickle cell anemia
Patrick T. McGann et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members
Barbara P. Yawn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
Camila Bononi Almeida et al.
BLOOD (2012)
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
Vladan P. Cokic et al.
BLOOD (2008)
Nitric oxide production from hydroxyurea
SB King
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Share Paper
